ArticleDiscover oncology2025
Outcomes of secondary primary malignancies among patients with diffuse large B-cell lymphoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAn increased risk of secondary primary malignancies (SPMs) has been shown in diffuse large B-cell lymphoma (DLBCL) patients after treatment. However, research on SPM outcomes in DLBCL patients is limited.
methodsUtilizing the population-based Surveillance, Epidemiology, and End Results Registry (SEER), the authors examined the characteristics, overall survival (OS), and treatments in DLBCL patients who developed secondary cancers of the breast, prostate, lung, colon/rectum, bladder cancers, melanoma, myeloma, and acute leukemia. Each patient was matched by age, sex, race, year of diagnosis, and stage to 50 controls from a general population diagnosed with a non-DLBCL primary the cancer.
resultsPatients with antecedent DLBCL who developed lung cancer (37.3% vs. 18.3%, P < 0.001) or colon/rectum cancer (45.5% vs. 39.6%, P = 0.032) were more commonly diagnosed at an early stage. Compared with patients in the control group, patients with antecedent DLBCL who developed prostate cancer, melanoma, myeloma, and acute leukemia had significantly worse OS. Conversely, patients who developed lung cancer after their antecedent DLBCL diagnosis showed markedly better OS. Amongst patients with antecedent DLBCL aged over 60, intensive therapy was associated with improved OS compared to supportive care in those being treated for a SPM diagnosis of breast, prostate, lung, colon/rectum, melanoma or bladder cancer, but not myeloma or acute leukemia. The rates of surgical resection were the same between patients with antecedent DLBCL and those in the control group, except for lower prostatectomy rates and higher lobectomy rates among patients with antecedent DLBCL.
conclusionsOur findings can assist clinicians in better understanding the survival outcomes of SPMs among patients with antecedent DLBCL while suggesting that long-term follow-up might be useful to detect DLBCL survivors who developed SPMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.